The Technical Analyst
Processa Pharmaceuticals, [PCSA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Processa Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.25% $1.620
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.63 mill |
| EPS: | -8.48 |
| P/E: | -0.190 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 2.86 mill |
| Avg Daily Volume: | 1.627 mill |
| RATING 2024-04-24 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.190 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -0.190 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.47 (114.41%) $1.853 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.393 - 1.927 ( +/- 16.08%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-01 | Young David | Buy | 1 675 | Common Stock |
| 2024-01-01 | Young David | Sell | 518 | Common Stock |
| 2024-01-01 | Young David | Sell | 1 675 | Restricted Stock Units |
| 2024-01-01 | Stanker James H | Sell | 1 675 | Restricted Stock Units |
| 2024-01-01 | Stanker James H | Buy | 1 675 | Common Stock |
| INSIDER POWER |
|---|
| 80.24 |
| Last 99 transactions |
| Buy: 3 005 145 | Sell: 402 801 |
Forecast:
16:00 - $1.670
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.670
Forecast 2: 16:00 - $1.670
Forecast 3: 16:00 - $1.670
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.620 (1.25% ) |
| Volume | 0.0396 mill |
| Avg. Vol. | 1.627 mill |
| % of Avg. Vol | 2.43 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PCSA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $2.36 | N/A | Active |
|---|
PCSA
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Latest Press Releases
2024-03-28 08:15:00 - Press Release
Processa Pharmaceuticals To Present At The Medinvest Biotech And Pharma Investor Conference
Hanover, md, march 28, 2024 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that george ng, chief executive officer, will present a corporate update at the medinvest biotech and pharma investor conference. david young, processa's president of research & development, will participate virtually.
2024-03-25 08:15:00 - Press Release
Processa Pharmaceuticals To Present Data At The American Association For Cancer Research Annual Meeting
Hanover, md, march 25, 2024 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that the company will have two posters at the american association for cancer research annual meeting 2024 in san diego from april 5-10, 2024.
2024-02-21 08:15:00 - Press Release
Processa Pharmaceuticals To Present At The 2024 Bio Ceo & Investor Conference
Hanover, md, feb. 21, 2024 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that chief executive officer george ng will present a corporate update at the 2024 bio ceo & investor conference being held on february 26 – 27, 2024 at the marriott marquis in new york city.
2024-02-14 13:00:00 - Press Release
Processa Pharmaceuticals To Present At The Winter Wrap-up Microcap Rodeo Winter 2024 Virtual Conference
Hanover, md, feb. 14, 2024 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces that ceo george ng will present a corporate update at the winter wrap-up microcap rodeo 2024 virtual conference being held february 20 – 23, 2024.
2024-02-06 08:30:00 - Press Release
Processa Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Rule
Hanover, md, feb. 06, 2024 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces it has received notice from the nasdaq stock market llc (“nasdaq”) informing the company that it has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550(a)(2) (the “rule”) for continued listing on the nasdaq market and that the matter is now closed.
Latest News
2024-03-28 08:15:00 - GlobeNewsWire
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that George Ng, Chief Executive Officer, will present a corporate update at the MedInvest Biotech and Pharma Investor Conference. David Young, Processa's President of Research & Development, will participate virtually.
2024-03-25 08:15:00 - GlobeNewsWire
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that the Company will have two posters at the American Association for Cancer Research Annual Meeting 2024 in San Diego from April 5-10, 2024.
2024-02-21 08:15:00 - GlobeNewsWire
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Chief Executive Officer George Ng will present a corporate update at the 2024 BIO CEO & Investor Conference being held on February 26 – 27, 2024 at the Marriott Marquis in New York City.
2024-02-14 13:00:00 - GlobeNewsWire
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces that CEO George Ng will present a corporate update at The Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference being held February 20 – 23, 2024.
2024-01-25 14:40:30 - InvestorPlace
Why Is Processa Therapeutics (PCSA) Stock Up 90% Today?
Clinical-stage pharmaceutical company Processa Therapeutics (NASDAQ: PCSA ) — which specializes in the field of oncology — is skyrocketing on Thursday. PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today.
2024-01-25 11:29:11 - Invezz
What made Processa Pharmaceuticals stock nearly triple on Thursday?
Processa Pharmaceuticals Inc (NASDAQ: PCSA) says it has completed a safety evaluation of its cancer treatment. Its shares rallied well over 150% on Thursday.
2024-01-02 17:06:00 - GlobeNewsWire
Processa Pharmaceuticals to Present at the Biotech Showcase 2024
HANOVER, MD, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that George Ng, Chief Executive Officer, will present a corporate overview at the Biotech Showcase 2024. The event is being held at the Hilton San Francisco Union Square on January 8 – 10, 2024.
2023-11-30 08:15:00 - GlobeNewsWire
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
HANOVER, MD, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Dr. David Young, President of Research and Development, will present virtually at the MedInvest Oncology Investor Conference.
2023-11-09 08:15:00 - GlobeNewsWire
Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
HANOVER, MD, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Dr. David Young, President of Research and Development, will present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas.
2023-10-19 10:32:58 - PennyStocks
Best Penny Stocks Under $1? 4 To Watch This Week
What are the best penny stocks under $1? If you saw this headline, that's probably a question you have heading into the second half of the week.